Overbrook Management Corp bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 56,111 shares of the biopharmaceutical company’s stock, valued at approximately $139,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Parametric Portfolio Associates LLC raised its stake in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 1,409 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 1,433 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 2,453 shares in the last quarter. American International Group Inc. raised its stake in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 3,880 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Celldex Therapeutics by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock valued at $1,943,000 after purchasing an additional 5,616 shares in the last quarter. Institutional investors and hedge funds own 56.69% of the company’s stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 1.88% on Wednesday, reaching $2.61. The company’s stock had a trading volume of 1,324,063 shares. Celldex Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.02. The company’s market cap is $334.97 million. The company has a 50-day moving average price of $2.45 and a 200 day moving average price of $2.87.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The company’s revenue was up 175.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Overbrook Management Corp Invests $139,000 in Celldex Therapeutics, Inc. (CLDX)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/13/overbrook-management-corp-invests-139000-in-celldex-therapeutics-inc-cldx.html.

A number of brokerages recently commented on CLDX. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $7.32.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.